FindTrial
Sign In

The study of different doses of d-ketamine combined with sufentanil for postoperative patient-controlled intravenous analgesia in patients with laparoscopic total hysterectomy

The study of different doses of d-ketamine combined with sufentanil for postoperative patient-controlled intravenous analgesia in patients with laparoscopic total hysterectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089855
Enrollment
Unknown
Registered
2024-09-18
Start date
2022-05-12
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine lesions

Interventions

Group N:Postoperative analgesic pump ratio:Sufentanil 3.0µg/kg + metoclopramide 20mg + normal saline diluted to 100ml
Group A1:Postoperative analgesic pump ratio:D-ketamine 0.25 mg/kg + sufentanil 2.0 µg/kg + metoclopramide 20 mg + normal saline diluted to 100 ml
Group A2:Postoperative analgesic pump ratio:D-ketamine 0.5mg/kg + sufentanil 2.0µg/kg + metoclopramide 20mg + normal saline diluted to 100ml
Group A3:Postoperative analgesic pump ratio:D-ketamine 1.0mg/kg + sufentanil 2.0µg/kg + metoclopramide 20mg + normal saline diluted to 100ml

Sponsors

The Second Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) The patient is going to undergo laparoscopic total hysterectomy, ASA grade I-II; (2) The age of the patient is =40 years old and =60 years old; (3) The patient's body mass index (BMI) is 19-24 kg/m2; (4) The patient's communication is normal, and he has a certain learning ability.

Exclusion criteria

Exclusion criteria: (1) Severe respiratory and circulatory system diseases: such as combined with severe coronary atherosclerosis, acute myocardial infarction, respiratory failure and other basic diseases; (2) Nervous system diseases: such as severe cerebral hemorrhage or sequelae of cerebral infarction, hemiplegia, aphasia, etc.; (3) Mental and psychological diseases: such as schizophrenia, depression, etc.; (4) Long-term abuse of analgesics, history of chronic pain, etc.; (5) Combined with obvious abnormal liver and kidney function; (6) Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Optimal PCIA compatible dose of D-ketamine;—

Secondary

MeasureTime frame
Visual Analogue Scale (VAS) Pain Score;Ramsay sedation scores;Bruggrmann comfort scale;PCIA total and effective compressions;Total consumption of sufentanil;Remedial pain relief;Adverse reactions;QoR-15;—

Countries

China

Contacts

Public ContactXianwen Hu

The Second Hospital of Anhui Medical University

huxianwen001@163.com+86 151 5515 9719

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026